Analyst Price Targets — CTNM
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 8, 2026 11:19 am | — | Morgan Stanley | $14.00 | $9.56 | TheFly | Contineum downgraded to Equal Weight from Overweight at Morgan Stanley |
| November 24, 2025 12:33 pm | — | Robert W. Baird | $14.00 | $10.95 | TheFly | Contineum price target lowered to $14 from $16 at Baird |
| November 21, 2025 1:42 pm | Brian Abrahams | RBC Capital | $22.00 | $12.22 | TheFly | Contineum price target lowered to $22 from $25 at RBC Capital |
| September 25, 2025 10:06 am | — | Leerink Partners | $20.00 | $10.86 | TheFly | Contineum initiated with an Outperform at Leerink |
| March 7, 2025 12:33 pm | — | Robert W. Baird | $16.00 | $6.77 | TheFly | Contineum price target lowered to $16 from $32 at Baird |
| October 21, 2024 4:54 pm | Joel Beatty | Robert W. Baird | $32.00 | $16.07 | StreetInsider | Baird Starts Contineum Therapeutics (CTNM) at Outperform |
| April 30, 2024 4:46 am | Brian Abrahams | RBC Capital | $30.00 | $16.00 | TheFly | Contineum initiated with an Outperform at RBC Capital |
| April 30, 2024 2:35 am | Paul Matteis | Stifel Nicolaus | $29.00 | $16.00 | StreetInsider | Stifel Starts Contineum Therapeutics (CTNM) at Buy |
Latest News for CTNM
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that on February 17, 2026 (Grant Date), the Compensation Committee of the Company's Board of Directors granted an inducement award consisting…
Here is how Contineum Therapeutics, Inc. (CTNM) and Quest Diagnostics (DGX) have performed compared to their sector so far this year.
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that on January 26, 2026 (Grant Date), the Compensation Committee of the Company's Board of Directors granted an inducement award consisting…
Contineum Therapeutics, Inc. (CTNM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The average of price targets set by Wall Street analysts indicates a potential upside of 91.5% in Contineum Therapeutics, Inc. (CTNM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CTNM.
U.S. House Trading
No House trades found for CTNM.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.